Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00373490
Status:
COMPLETED
Last Update Posted:
2015-08-27
First Post:
2006-09-07
Brief Title:
A Study of Oral Suberoylanilide Hydroxamic Acid Vorinostat in Patients With Solid Tumors 0683-048
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
MK0683 Phase1 Clinical Study - Solid Tumor -
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose MTD of MK-0683 vorinostat in a Japanese patient population with solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006_030 | None | None | None |
| MK0683-048 | None | None | None |